Dr Mark Cook is a Consultant Haematologist at the Queen Elizabeth Hospital Birmingham (QEHB). Based in the Centre for Clinical Haematology, Mark has a strong clinical focus on myeloma, and is Chief Investigator of a number of ongoing clinical trials in this area including the LENARIC trial.
Consultant Haematologist, Queen Elizabeth Hospital Birmingham
Lead Cancer Clinician, University Hospital Birmingham
Associate Director, Research and Development (Cancer), University Hospital Birmingham
Background and Research focus
Mark is a clinical haematologist based in the Centre for Clinical Haematology, Birmingham. He originally qualified from University of Bristol Medical School in 1998, and after specialist clinical training, he then joined the School of Cancer Sciences at the University of Birmingham in 2002. There he studied for a PhD on the immunogenetics of Killer Immunoglobulin-like Receptor and their impact on haematopoietic stem cell transplantation outcome, under the supervision of Professor Paul Moss and Professor David Briggs. Following successful completion of his PhD, he was appointed at UHB in 2004, became Clinical Service Lead for haematology in 2006, and was appointed as Associate Director of Research and Development (Cancer) at UHB in 2014.
Mark has strong clinical experience across a diverse range of haematological malignancies. He also has extensive experience of supporting early phase clinical trials, including for adjunctive targeted therapies (e.g. kinase inhibitors, and epigenetic modifiers) to improve outcome after allogeneic stem cell transplantation treatment for malignancies such as chronic myeloid leukaemia and acute myeloid leukaemia. A major current focus is on multiple myeloma, where Mark has developed an active trials programme. Specifically, he is Chief Investigator of LenaRIC, a Phase II trial of adjuvant use of lenalidomide in multiple myeloma patients undergoing reduced intensity conditioning allogeneic transplantation. Mark also has a research interest in renal function in multiple myeloma patients, and is Haematological lead for a clinical trial testing combined dialysis and chemotherapy as a strategy to restore renal function in patients with myeloma kidney disease (EuLITE).
Haematological malignancies; multiple myeloma; stem cell transplantation; autologous; allogeneic; conditioning regimens; reduced intensity conditioning; renal function; chemotherapy; immunogenetics; clinical trials; research and development; kinase inhibitors; epigenetic modification; killer immunoglobulin-like receptors; polymorphisms.
In addition to his own research, Mark is a member of the NCRI Clinical Studies Sub-Group for Myeloma and the UK Myeloma Forum Guidelines committee.
Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA, Drayson MT, Dispenzieri A, Leung N; International Kidney and Monoclonal Gammopathy Research Group. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013 Nov 21;122(22):3583-90.
Cockwell P, Cook M. The rationale and evidence base for the direct removal of serum-free light chains in the management of myeloma kidney. Adv Chronic Kidney Dis. 2012 Sep;19(5):324-32.
Stringer S, Cook M, Cockwell P. Achieving an early myeloma response in patients with kidney impairment. Adv Chronic Kidney Dis. 2012 Sep;19(5):303-11. Review.
Hutchison CA, Bladé J, Cockwell P, Cook M, Drayson M, Fermand JP, Kastritis E, Kyle R, Leung N, Pasquali S, Winearls C; International Kidney and Monoclonal Gammopathy Research Group. Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol. 2012 Feb 21;8(4):234-43.
Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012 Apr 5;119(14):3361-9.
McLarnon A, Piper KP, Goodyear OC, Arrazi JM, Mahendra P, Cook M, Clark F, Pratt G, Craddock C, Moss PA. CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica. 2010 Sep;95(9):1572-8.
Popat R, Oakervee H, Williams C, Cook M, Craddock C, Basu S, Singer C, Harding S, Foot N, Hallam S, Odeh L, Joel S, Cavenagh J. Bortezomib, low-dose intravenous melphalan, and dexamethasone for patients with relapsed multiple myeloma. Br J Haematol. 2009 Mar;144(6):887-94.
Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation. Blood. 2006 Feb 1;107(3):1230-2.
Cook MA, Milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC. The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia. Blood. 2004 Feb 15;103(4):1521-6.
Cook MA, Moss PA, Briggs DC. The distribution of 13 killer-cell immunoglobulin-like receptor loci in UK blood donors from three ethnic groups. Eur J Immunogenet. 2003 Jun;30(3):213-21.